End Disparity in Drug Prices to Aid Patients

Published: 21st July 2014 06:00 AM  |   Last Updated: 21st July 2014 01:24 AM   |  A+A-

The National Pharmaceutical Pricing Authority’s decision to cap the ceiling prices of 108 anti-diabetes and cardiovascular formulations has upset the drug industry, which is up in arms against the order. When the industry argues these medicines don’t come within the purview of either Schedule-I drugs or essential drugs, it only betrays its ignorance of the Drug Prices Control Order, 2013, that empowers the NPPA to fix the price of any drug “in public interest”. The authority cannot, hence, be faulted for its decision. Diabetes and cardiovascular diseases are, by and large, lifestyle-induced. Consequently, the number of people suffering from these diseases has been rising.

This itself shows that anti-diabetes and cardiovascular formulations can only be described as essential drugs. Unlike consumer goods which people can choose depending on their affordability, the patients are helpless when it comes to drugs. They have to buy whatever medicines the doctors prescribe, as they do not have any knowledge about the compositions of the medicines. It is also well-known that most doctors are influenced by sales promotion by the pharmaceutical companies. It is also not uncommon for such companies to bribe doctors indirectly, if not directly, by giving them incentives to prescribe their medicines. Forget the differences in the prices of generic drugs and branded drugs, there is a huge difference in the prices of the same medicines manufactured by different companies.

True, market forces should guide the manufacturing and pricing of drugs. This would have ensured competitive pricing, which would have benefited the consumer. Even in case of drugs that have become generic, there is a huge difference in their prices when they are manufactured and sold by different companies under different brand names. This is tantamount to pricing the same molecules differently. If the market cannot correct this anomaly, state intervention is necessary in the public interest. Instead of finding fault with the NPPA’s decision, the drug industry would do well to remove the disparities in the prices in the interest of patients, who are mostly poor.

Stay up to date on all the latest Editorials news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp